A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM(197)...

por Thuluva, Subhash, Paradkar, Vikram, Matur, Ramesh, Turaga, Kishore, GV, Subba Reddy
Publicado 2022

A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9–12 month old healthy infants

por Thuluva, Subhash, Gunneri, SubbaReddy, Turaga, Kishore, Mogulla, Rammohan Reddy, Yerroju, Vijay, Peta, Kalyankumar, Suneetha, Pothakamuri Venkata, Matur, Ramesh V.
Publicado 2023

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised ph...

por Thuluva, Subhash, Paradkar, Vikram, Gunneri, Subba Reddy, Yerroju, Vijay, Mogulla, Rammohan, Turaga, Kishore, Kyasani, Mahesh, Manoharan, Senthil Kumar, Medigeshi, Guruprasad, Singh, Janmejay, Shaman, Heena, Singh, Chandramani, Rao A, Venkateshwar
Publicado 2022

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical...

por Thuluva, Subhash, Paradkar, Vikram, Gunneri, SubbaReddy, Yerroju, Vijay, Mogulla, Rammohan, Suneetha, Pothakamuri Venkata, Turaga, Kishore, Kyasani, Mahesh, Manoharan, Senthil Kumar, Adabala, Srikanth, Sri Javvadi, Aditya, Medigeshi, Guruprasad, Singh, Janmejay, Shaman, Heena, Binayke, Akshay, Zaheer, Aymaan, Awasthi, Amit, Singh, Chandramani, Rao A, Venkateshwar, Basu, Indranil, Kumar, Khobragade Akash Ashok, Pandey, Anil Kumar
Publicado 2023